Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Discontinuing development of istisociclib, a CDK9 inhibitor; benefit-risk profile in platinum-resistant high-grade serous ovarian cancer does ...

Q3 2024 revenue was $6.1 million, which comprises $6.6 million in core product and software sales which is offset by $0.5 million because of a write-down of aged receivables tied to discontinued ...